BioNTech SE (22UA) — Financial Flexibility Index

Latest as of March 2026: -0.14x

BioNTech SE (22UA) has a Financial Flexibility Index of -0.14x as of March 2026. Free cash flow of €-342.10 Million (operating CF €-421.00 Million minus capex €78.90 Million) represents 0% of total liabilities (€2.38 Billion). Check cash flow reinvestment rate of BioNTech SE to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-0.14x
Free Cash Flow / Total Liabilities

Free Cash Flow

€-342.10 Million
Operating CF − Capex

Total Liabilities

€2.38 Billion
EUR

Capital Expenditures

€78.90 Million
EUR

BioNTech SE Financial Flexibility Index (2017–2025)

Historical Financial Flexibility Index trend for BioNTech SE across 9 annual periods. For the full cash flow conversion analysis, see BioNTech SE (22UA) cash flow conversion.

Annual Financial Flexibility Index for BioNTech SE (2017–2025)

Year-by-year free cash flow to debt coverage for BioNTech SE. Explore cash flow to debt ratio of BioNTech SE to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 0.44x €1.21 Billion €456.00 Million €2.76 Billion ▲ +106.0%
2024 0.21x €660.00 Million €207.70 Million €3.12 Billion ▼ -90.4%
2023 2.20x €6.08 Billion €5.37 Billion €2.76 Billion ▼ -49.1%
2022 4.32x €13.94 Billion €13.58 Billion €3.22 Billion ▲ +1573.9%
2021 0.26x €1.02 Billion €889.70 Million €3.94 Billion ▲ +365.9%
2020 0.06x €52.50 Million €-13.50 Million €946.77 Million ▲ +110.5%
2019 -0.53x €-159.90 Million €-198.50 Million €304.15 Million ▼ -600.3%
2018 -0.08x €-28.98 Million €-58.88 Million €385.99 Million ▼ -12.4%
2017 -0.07x €-28.24 Million €-52.56 Million €422.92 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities